These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 469103)

  • 1. The use of behavior modification techniques for the treatment of hemodialysis patient non-compliance: a case study.
    Wenerowicz WJ
    J Dial; 1979; 3(1):41-50. PubMed ID: 469103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contingent social reinforcement for fluid compliance in a hemodialysis patient.
    Mosley TH; Eisen AR; Bruce BK; Brantley PJ; Cocke TB
    J Behav Ther Exp Psychiatry; 1993 Mar; 24(1):77-81. PubMed ID: 8370800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodialysis without heparin infusion using Cordis Dow 3500 hollow fiber.
    Raja R; Kramer M; Rosenbaum JL; Bolisay C; Krug M
    Proc Clin Dial Transplant Forum; 1980; 10():39-42. PubMed ID: 7346852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.
    Sánchez-Canel JJ; Pons-Prades R; Salvetti ML; Seores A; Vázquez M; Pérez-Alba A; Tamarit E; Calvo-Gordo C; Villatoro J
    Nefrologia; 2012; 32(5):605-12. PubMed ID: 23013946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence of hemodialysis, heparin and protamin on the pre-beta fraction of lipoproteins in patients with chronic kidney failure].
    Koslík S; Takác M; Koslíkova G
    Z Gesamte Inn Med; 1977 Dec; 32(23):658-61. PubMed ID: 204117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Use of activated coagulation time for evaluation of the degree of heparinization and calculation of heparin pharmacokinetic parameters during hemodialysis].
    Khodas MIa; Piatnitskaia GKh; Lanskaia IM; Maksimenko VA; Savina ME
    Urol Nefrol (Mosk); 1988; (3):42-8. PubMed ID: 3218006
    [No Abstract]   [Full Text] [Related]  

  • 7. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
    Stefoni S; Cianciolo G; Donati G; Colì L; La Manna G; Raimondi C; Dalmastri V; Orlandi V; D'Addio F
    Nephron; 2002; 92(3):589-600. PubMed ID: 12372942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clotting by heparin of hemoaccess for hemodialysis in an end-stage renal disease patient.
    Pham PT; Miller JM; Demetrion G; Lew SQ
    Am J Kidney Dis; 1995 Apr; 25(4):642-7. PubMed ID: 7702065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Individual dosage schedule of heparin therapy in chronic hemodialysis by analytic studies of blood coagulation].
    Gläser V; Anstadt M
    Z Urol Nephrol; 1990 Mar; 83(3):133-40. PubMed ID: 2356667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of PEG-Hirudin in chronic hemodialysis monitored by the Ecarin Clotting Time: influence on clotting of the extracorporeal system and hemostatic parameters.
    Ulbricht K; Bucha E; Pöschel KA; Stein G; Wolf G; Nowak G
    Clin Nephrol; 2006 Mar; 65(3):180-90. PubMed ID: 16550749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heparin free dialysis: comparative data and results in high risk patients.
    Caruana RJ; Raja RM; Bush JV; Kramer MS; Goldstein SJ
    Kidney Int; 1987 Jun; 31(6):1351-5. PubMed ID: 3613407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Behavioral contracting to improve dietary compliance in chronic renal dialysis patients.
    Keane TM; Prue DM; Collins FL
    J Behav Ther Exp Psychiatry; 1981 Mar; 12(1):63-7. PubMed ID: 7251883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine clinical applications of hemodialysis-hemoperfusion in chronic renal failure: case reports.
    Barré PE; Gonda A; Chang TM
    Int J Artif Organs; 1986 Sep; 9(5):305-8. PubMed ID: 3023242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of a token economy on dietary compliance for children on hemodialysis.
    Magrab PR; Papadopoulou ZL
    J Appl Behav Anal; 1977; 10(4):573-8. PubMed ID: 599104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of anticoagulation on blood membrane interactions during hemodialysis.
    Hofbauer R; Moser D; Frass M; Oberbauer R; Kaye AD; Wagner O; Kapiotis S; Druml W
    Kidney Int; 1999 Oct; 56(4):1578-83. PubMed ID: 10504511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peritoneal dialysis is the therapy of choice for end-stage renal disease patients with hereditary clotting disorders.
    Bajo MA; del Peso G; Jiménez V; Aguilera A; Villar A; Jiménez C; Selgas R
    Adv Perit Dial; 2000; 16():170-3. PubMed ID: 11045286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin elimination and hemostasis in hemodialysis.
    Wilhelmsson S; Lins LE
    Clin Nephrol; 1984 Dec; 22(6):303-6. PubMed ID: 6525772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Problems Associated With Access to Renal Replacement Therapy: Experience of the Sindh Institute of Urology and Transplantation.
    Mazhar F; Nizam N; Fatima N; Siraj S; Rizvi SA
    Exp Clin Transplant; 2017 Feb; 15(Suppl 1):46-49. PubMed ID: 28260431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical usefulness of heparin-coated dialyzers].
    Kopeć J; Sułowicz W
    Przegl Lek; 2014; 71(8):430-2. PubMed ID: 25546914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of anticoagulation in hemodialysis patients.
    Biggers JA; Remmers AR; Glassford DM; Sarles HE; Lindley JD; Fish JC
    Nephron; 1977; 18(2):109-13. PubMed ID: 854139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.